About
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Research context
Torrent Pharmaceuticals Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Torrent Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 10.7% above its 200 day moving average.
From a valuation standpoint, the stock is 12.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Torrent Pharmaceuticals Limited's total revenue rose by 0.3% to $20B since the same quarter in the previous year.
Its net income has increased by 18.3% to $3B since the same quarter in the previous year.
Finally, its free cash flow grew by 58.1% to $11B since the same quarter in the previous year.
Based on the above factors, Torrent Pharmaceuticals Limited gets an overall score of 4/5.